Predicting the quality of anticoagulation during warfarin therapy: The basis for an individualized approach

Chest

Volumn 144, Issue 5, 2013, Pages 1437-1438

  Boriani, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; CYTOCHROME; CYTOCHROME 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ANTICOAGULATION; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; CYP2C9 GENE; DRUG COST; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EDITORIAL; GENE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HEALTH CARE QUALITY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VKORC GENE;

EID: 84887480872     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1285     Document Type: Editorial

References (12)

1. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl Res. 2009;154(6):277-287.
2. Jorgensen AL, Al-Zubiedi S, Zhang JE, et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics. 2009;19(10):800-812.
3. International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data [published correction appears in N Engl J Med. 2009;361(16):1613]. N Engl J Med. 2009;360(8):753-764.
4. Apostolakis S, Sullivan RM, Olshansky B, Lip G Y H. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT 2 R 2 score. Chest. 2013;144(5):1555-1563.
5. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(2):84-91.
6. Van Den Ham HA, Klungel OH, Leufkens HG, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost. 2013;11(1):107-115.
7. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333.
8. Kirchhof P, Lip GY, Van Gelder IC, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options-a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012;14(1):8-27.
9. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5(5):615-621.
10. Lip G Y H, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489-1498.
11. Boriani G, Diemberger I. Globalization of the epidemiologic, clinical, and financial burden of atrial fibrillation. Chest. 2012;142(6):1368-1370.
12. Boriani G, Diemberger I, Biffi M, Martignani C. Balancing the risk of hemorrhage vs thromboembolism in patients with atrial fibrillation: how to navigate between scylla and charybdis? Chest. 2010;138(5):1032-1033.